Navigation Links
Odyssey Thera Announces Collaboration With Mitsubishi Tanabe Pharma Corporation, and Issuance of Core Patent in Japan
Date:5/15/2009

SAN RAMON, Calif., May 15 /PRNewswire/ -- Odyssey Thera, Inc. announced today the initiation of a collaboration with leading Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation. The alliance involves the analysis of drug candidates from a number of Mitsubishi Tanabe preclinical programs. Odyssey also announced the issuance of Japanese patent number JP 4262778, entitled "Protein fragment complementation assays for the detection of biological or drug interactions."

"We look forward to applying our patented human cell analysis technologies and proprietary drug profiling strategies to enhance Mitsubishi Tanabe's promising drug discovery programs," said Dr. John Westwick, President and CEO of Odyssey Thera. "Our partnership with Mitsubishi Tanabe, and the issuance of our Japanese patent, reflect our objective of making our unique knowledge base and enabling technologies available to quality partners around the globe."

Odyssey Thera will apply its patented Protein-fragment Complementation Assay (PCA), proprietary High Context Screening infrastructure, unique institutional knowledge, and state-of-the-art data analysis strategies in the collaboration to yield valuable insights related to drug selectivity, safety, and mechanisms of action. Financial terms of the collaboration were not disclosed.

About Odyssey Thera

Odyssey Thera, Inc. is a drug discovery company committed to identifying novel drug candidates for oncology and other chronic diseases. Odyssey Thera's live cell, pathway-based approach centers on its proprietary Protein-fragment Complementation Assay (PCA) technology and unique High Context Screening platform. Using these capabilities, Odyssey scientists have gained unique knowledge regarding cellular pathways and drug mechanisms. Odyssey's highly experienced team is using these capabilities to mine cellular systems and discover novel drug candidates for internal programs, and in partnerships with top pharmaceutical companies. To learn more about Odyssey Thera, please visit www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
2. Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System
3. LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
6. Odyssey Thera Granted U.S. Patent for Animal Imaging
7. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
8. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
9. Orexigen(R) Therapeutics to Present at Upcoming Meetings
10. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
11. Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/9/2016)... in attendance control systems is proud to announce the introduction of fingerprint attendance control ... right employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
Breaking Biology News(10 mins):